

EQA round: APLA1/25 - Antiphospholipid Antibodies

Deadline: 14.3.2025

Setup: Slovakia

AV = assigned value	N _{tot} = total number of the results	N _{eva} = number of the results assessed
CVP = consensus of all participants	N _{rel} = relative number of the results	N _{suc} = number of successful results
>>> ... expected result		S _{rel} = relative success
> ... acceptable result		
± ... result not assessed		

Test Sample Group	Frequency of the results				Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]
(465) anti-β2-glycoprotein 1 screening		5			5	5	100
Sample A		5			5	5	100
All results	CVP >>>	5	100	Positive			
Sample B		5			5	5	100
All results	CVP >>>	5	100	Negative			
(467) anti-β2-glycoprotein 1 IgG		12			12	11	92
Sample A		12			12	11	92
All results		1	8,3	Negative			
	CVP >>>	11	92	Positive			
Sample B		12			12	12	100
All results	CVP >>>	12	100	Negative			
(468) anti-β2-glycoprotein 1 IgM		12			12	12	100
Sample A		12			12	12	100
All results	CVP >>>	12	100	Negative			
Sample B		12			12	12	100
All results	CVP >>>	12	100	Negative			
(461) anti-cardiolipin screening		6			6	6	100
Sample A		6			6	6	100
All results	CVP >>>	6	100	Positive			
Sample B		6			6	6	100
All results	CVP >>>	6	100	Negative			
(463) anti-cardiolipin IgG		12			12	12	100
Sample A		12			12	12	100
All results	CVP >>>	12	100	Positive			
Sample B		12			12	12	100
All results	CVP >>>	12	100	Negative			
(464) anti-cardiolipin IgM		12			12	12	100
Sample A		12			12	12	100
All results	CVP >>>	12	100	Negative			
Sample B		12			12	12	100
All results	CVP >>>	12	100	Negative			